TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioline RX Ltd Sponsored ADR ( (BLRX) ) has provided an update.
On November 17, 2025, BioLineRx Ltd. announced that the USPTO has issued a Notice of Allowance for a patent covering the use of GLIX1 for treating a broad range of cancer types where cytidine deaminase is not over-expressed. This patent, which extends protection until 2040, strengthens BioLineRx’s intellectual property and supports their expansion of GLIX1 development beyond glioblastoma into other cancers. The patent’s allowance is pivotal as it secures BioLineRx’s ability to explore GLIX1’s potential across the majority of cancers, with clinical trials for glioblastoma expected to start in early 2026.
The most recent analyst rating on (BLRX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
Bioline RX Ltd’s overall stock score reflects significant revenue growth and promising pipeline developments. However, ongoing financial challenges, including negative net income and high leverage, weigh heavily on the score. The technical indicators suggest a bearish trend, and the valuation highlights the lack of immediate investor returns. The earnings call provides some optimism for future growth, but financial and operational challenges maintain a balanced outlook.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical development stage biopharmaceutical company focused on developing therapies for oncology and rare diseases. Their first approved product, APHEXDA, is used for stem cell mobilization in multiple myeloma. The company is also working on GLIX1, a small molecule targeting DNA damage response in glioblastoma and other cancers.
Average Trading Volume: 35,761
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.37M
For detailed information about BLRX stock, go to TipRanks’ Stock Analysis page.